Influenza is a viral respiratory infection that affects tens of thousands of

people every year. Each year, the marketed influenza vaccines target the most

commonly predicted strains. However, even with the moderate success of the 2019 fluvaccine at 47% protective, there still remains some shortcomings for the currentlymarketed flu vaccinations. Hence, to potentially overcome inssues with cross-protectivity, another approach involves utilizing a matrix protein, matrix-2 protein (M2e),which is a highly conserved protein in A strains of the influenza virus. To increase the immunogenicity of M2e, multiple repeats of the protein were combined to form a virus-l ike particle (VLP). The VLP was then encapsulated into a polymeric microparticulate(MP) formulation to improve uptake by antigen presenting cells (APCs) and induce long

term antigen release in the body. Additionally, many individuals do not receive the fluvaccine currently because of invasive intramuscular injections. Therefore, the proposedVLP MP vaccine was delivered transdermally through various devices and vaccineefficacy was compared to that of more traditional routes of administration.